Solving Delivery Of Gene Therapy For Control Of Human Immunodeficiency Virus Infection
Funder
National Health and Medical Research Council
Funding Amount
$765,439.00
Summary
Antiretroviral therapy free control of Human Immunodeficiency Virus (HIV) infection requires control of the viral reservoir. We have a unique approach, aimed at enforcing HIV latency by targeting highly conserved regions in the viral promoter. These constructs completely silence viral transcription for long periods of time. We intend to develop & assess vectors that are specifically targeted to the reservoir and which can enforce viral latency despite immune activation or viral variation.
HIV Assembly, Transport, Egress And Transfer From Infected Dendritic Cells
Funder
National Health and Medical Research Council
Funding Amount
$511,629.00
Summary
HIV-AIDS is the fourth leading killing disease worldwide, with the disease burden shifting towards women. Study of the HIV life cycle in cells known to be targetted during HIV transmission is key towards designing additional preventative measures in the form of topical gels known as microbicides. Mapping of the basic pathways of viral transport within such cells, will aid further drug discovery and-or appropriateness of use of existing drugs in microbicide formulations.
HIV-1 Transcriptional Gene Silencing By Promoter Targeted Si/shRNAs: Uncovering Mechanisms, Optimising Delivery Systems, Assessing In Vivo Efficacy.
Funder
National Health and Medical Research Council
Funding Amount
$641,789.00
Summary
Current therapy for HIV is effective but must be taken for life. If therapy is stopped the virus comes back immediately from reservoirs not affected by current drugs. These fluctuating levels of virus are associated with increased illness and death. We are exploring a method of inducing prolonged viral latency using short double stranded RNA molecules. We propose to understand the mechanism of action of these possible therapeutics and to develop these constructs towards use in clinical trials.